In 90% of cases of pancreatic cancer, the two-year survival rate is barely 10%. And this hope lies in the Messenger RNA, which allows the tailor-made creation of a vaccine.
Once injected, the vaccine allows the immune system to attack tumors on its own. Results: out of sixteen patients treated, eight developed cells capable of destroying cancer. A year and a half later, there has been no relapse. The researchers plan to launch a large-scale trial this summer.